Novadaq Technologies Inc.TSX: NDQ

Novadaq reports financial results for third quarter of 2005

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, Nov. 10 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ) today
announced its financial results for the third quarter and nine months ended
September 30, 2005.
"Our initiatives in the third quarter were largely focused on
strengthening our position in the U.S. for the SPY(R) Intra-operative Imaging
System. The establishment of our U.S. subsidiary, the training of our Sorin
sales distribution partners, the hiring of our U.S. based clinical educators
and the appointment of two co-Chief Medical Advisors will help us to
accelerate SPY System placements and will ensure continued growth for Novadaq
in the world's largest medical technology market," said Arun Menawat,
President and CEO of Novadaq Technologies Inc. "Also in this quarter, we
further advanced our OPTTX(TM) program by initiating our clinical trial at
Toronto Western Hospital.

Key Developments

-  Ramped up placements of the SPY System through Sorin in key cardiac
   centers in the United States.
-  Hired U.S. based clinical educators to support sales to the cardiac
   surgery market.
-  Appointed two co-Chief Medical Advisors who will assist the Novadaq
   marketing team and clinical educators in the development and
   implementation of physician, hospital and payer targeted initiatives
   that will support efforts to establish the SPY System as a standard of
   care in cardiac surgery.
-  Advanced implementation of educational and marketing programs to
   support growth in sales and ensure continuous feedback from clinicians
   providing Novadaq with the credibility and critical mass to ramp up
   placements and meet commercialization goals.
-  Established a U.S. subsidiary to extend infrastructure and ensure
   support for sales growth in the world's largest medical technology
   market. Novadaq Corp. will be lead by General Manager, Rick Mangat,
   co-founder of Novadaq, co-inventor of the SPY System.
-  Executed on clinical advancement for the OPTTX System to treat wet AMD
   at Toronto Western Hospital, a leading center for the treatment of
   vascular diseases of the eye.

Financial Results

Revenue in 2005 Q3 was $222,425, representing an increase of $204,641
over revenue in 2004 Q3 of $17,784. $117,000 of this increase related to the
capital sale of a SPY imaging device outside the U.S. in September 2005. No
SPY imaging devices were sold in 2004 Q3. Approximately $88,000 of the
increase is attributable to increased procedural revenue, consumable supply
sales, and other non-capital sale revenue. The SPY System received regulatory
clearance in the United States in January 2005 and the first device was
installed in the United States in March 2005. As at September 30, 2005 there
were a total of 10 SPY imaging devices installed in the United States.
Cost of sales increased by $66,786 to $78,405 in 2005 Q3 as compared to
$11,620 in 2004 Q3. Gross profit for the period increased to $144,020 in 2005
Q3 from $6,164 in 2004 Q3. As a percentage of sales, gross profit increased to
65% in 2005 Q3 from 35% in 2004 Q3. The increase in gross profit percentage is
attributable primarily to the capital sale of a SPY imaging device in 2005 Q3.
The gross profit percentage earned on capital sales is higher than the
percentage earned on procedural revenue as the procedural gross profit is net
of sales commissions, and the cost of consumable supplies.
Sales and marketing expenses increased to $320,417 in 2005 Q3 from
$36,068 in 2004 Q3. The increase in sales and marketing expenses was a result
of the commercial launch of the SPY System in the United States in 2005, and
included an increase in employee and related office and travel costs
(approximately $227,000), as well as marketing materials and advertising
(approximately $58,000).
Research and development expenses increased by $532,719 to $801,870 in
2005 Q3 from $269,151 in 2004 Q3. This increase is related to several factors,
including design and manufacturing costs for next generation OPTTX devices for
use in clinical trials (increase of approximately $114,000), which are
currently in the testing phase. The overall increase also reflects employee
and related office and travel costs for additional engineering staff to
support design efforts, clinical staff to plan and execute OPTTX trials
(increase of approximately $289,000), increases in patent costs (approximately
$65,000) and regulatory consulting fees (approximately $37,000).
General and administration expenses increased by $230,019 to $511,727 in
2005 Q3 from $281,708 in 2004 Q3. This increase is related to increases in
employee, office and travel costs (approximately $98,000), increases in D&O
insurance (approximately $75,000) and increases in professional fees
(approximately $52,000).
Depreciation expense decreased by $9,586 from 2004 Q3 to 2005 Q3 as
certain SPY imaging devices that were being used in research and development
in 2004, were converted to revenue producing assets during 2005. Amortization
of these devices was included in depreciation expense in 2004 Q3 and cost of
sales in 2005 Q3. Amortization increased by $5,944 from 2004 Q3 to 2005 Q3 as
a result of license payments made in June 2005 which are capitalized and
amortized.
Interest income increased by $199,070 from 2004 Q3 to 2005 Q3 as a result
of the increase in cash and short term investment balances following
completion of the Company's initial public offering on June 10, 2005.
Net loss increased by $454,713 to $1,126,822 in 2005 Q3 from $672,109 in
2004 Q3. The increase in net loss was primarily related to increases in sales
and marketing expenses (approximately $284,000), research and development
expenses (approximately $532,000) and increased general and administrative
expenses (approximately $230,000). This was partially offset by increased
gross profit (approximately 138,000), increased foreign exchange gains
(approximately $252,000) and increased interest income (approximately
$199,000).
As at September 30, 2005 the Company had cash, cash equivalents and  
short-term investments of $24,941,017, an increase of $15,542,743 over
December 31, 2004. The increase in these balances was primarily the result of
the initial public offering completed on June 10, 2005 for net proceeds of
$17,850,019 offset by cash used in operations during 2005 YTD.
The number of common shares outstanding as of September 30, 2005 was
17,991,361.

Conference call

Novadaq will host a conference call on Thursday, November 10, 2005 at
4:30 p.m. ET to discuss its third quarter 2005 results. To access the
conference call by telephone, dial 1-800-814-4890 or 416-644-3427. Please
connect approximately ten minutes prior to the beginning of the call to ensure
participation. The conference call will be archived for replay until
November 17, 2005 at midnight. To access the archived conference call, dial
416-640-1917 or 1-877-289-8525 enter the reservation number 21160122 followed
by the number sign.
A live audio webcast of the conference call will be available at
www.novadaq.com. Again, please connect at least ten minutes prior to the
conference call to ensure adequate time for any software download that may be
required to join the webcast. The webcast will be archived at the above
website for 90 days

About Novadaq Technologies

Novadaq Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System enables surgeons to visually assess
coronary vasculature and bypass graft functionality during the course of
cardiac surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials.
For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

Summary financial statements attached:
For complete financial statements please go to www.sedar.com

<<

                      NOVADAQ TECHNOLOGIES INC.
                Incorporated under the laws of Canada

                           BALANCE SHEETS
                         (expressed in US$)
                              Unaudited

                                                    As at        As at
                                               September 30, December 31,
                                                    2005         2004
                                                      $            $
-------------------------------------------------------------------------

                               ASSETS
Current
Cash and cash equivalents                           181,604      434,380
Short-term investments                           24,759,413    8,963,894
Accounts receivable                                 210,267    1,082,659
Investment tax credits receivable                    41,352       54,468
Prepaid expenses and other receivables              530,458       58,644
Inventory                                            54,896       65,529
-------------------------------------------------------------------------
Total current assets                             25,777,990   10,659,574
-------------------------------------------------------------------------
Property, plant and equipment, net                  274,514       41,542
Deferred charges                                     13,198       19,015
Licenses, net                                     3,140,183    3,336,618
-------------------------------------------------------------------------
                                                 29,205,885   14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------

                LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities            934,438      478,692
Current portion of deferred revenue                  37,351       37,286
-------------------------------------------------------------------------
Total current liabilities                           971,789      515,978
-------------------------------------------------------------------------
Deferred revenue                                     31,126       59,206
-------------------------------------------------------------------------
Total liabilities                                 1,002,915      575,184
-------------------------------------------------------------------------

Shareholders' equity
Share capital                                    46,216,340   27,966,017
Contributed surplus                               3,384,331    2,280,891
Deficit                                         (21,397,701) (16,765,343)
-------------------------------------------------------------------------
Total shareholders' equity                       28,202,970   13,481,565
-------------------------------------------------------------------------
                                                 29,205,885   14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                   STATEMENTS OF LOSS AND DEFICIT
                         (expressed in US$)
                              Unaudited

                         Three months ended         Nine months ended
                            September 30,             September 30,
                          2005         2004         2005         2004
                            $            $            $            $
-------------------------------------------------------------------------

Revenue                   222,425       17,784      441,900       54,447
Cost of sales              78,405       11,620      155,976       34,778
-------------------------------------------------------------------------
Gross profit              144,020        6,164      285,924       19,669
-------------------------------------------------------------------------

Operating expenses
Sales and marketing       320,417       36,068      723,037      117,611
Research and
 development              801,870      269,151    2,469,443      842,634
General and
 administration           511,727      281,708    2,200,873    1,119,340
Depreciation                5,947       15,534       17,915       45,408
Amortization              109,472      103,528      321,435      303,561
Loss (gain) on foreign
 exchange                (263,343)     (11,537)    (474,697)      (8,192)
-------------------------------------------------------------------------
                        1,486,090      694,452    5,258,006    2,420,362
-------------------------------------------------------------------------
Loss before the
 following             (1,342,070)    (688,288)  (4,972,082)  (2,400,693)
Interest income           215,249       16,179      339,724       19,271
-------------------------------------------------------------------------
Net loss for the year  (1,126,821)    (672,109)  (4,632,358)  (2,381,422)

Deficit, beginning of
 period               (20,270,880) (15,701,792) (16,765,343) (15,701,792)
-------------------------------------------------------------------------
Deficit, end of
 period               (21,397,701) (16,373,901) (21,397,701) (18,083,214)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted
 loss per share             (0.06)       (0.05)       (0.28)       (0.18)
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                      STATEMENTS OF CASH FLOWS
                         (expressed in US$)
                              Unaudited

                         Three months ended         Nine months ended
                            September 30,             September 30,
                          2005         2004         2005         2004
                            $            $            $            $
-------------------------------------------------------------------------

OPERATING ACTIVITIES
Net loss for the
 period                (1,126,821)    (865,550)  (4,632,358)  (2,574,863)
Add (deduct) items not
 involving cash
  Depreciation and
   amortization           131,932      119,062      367,239      359,245
  Stock based
   compensation            34,500      228,000    1,103,440      568,000
-------------------------------------------------------------------------
                         (960,389)    (518,488)  (3,161,679)  (1,647,618)
Net change in non-cash
 working Capital
 balances related to
 operations              (654,599)    (150,740)     852,875      (48,116)
-------------------------------------------------------------------------
Cash (used) in
 operating activities  (1,614,988)    (669,228)  (2,308,804)  (1,695,734)
-------------------------------------------------------------------------

FINANCING ACTIVITIES
Issuance common
 shares, net                2,700    8,604,358   18,250,323    8,604,358
-------------------------------------------------------------------------
Cash provided by
 financing activities       2,700    8,604,358   18,250,323    8,604,358
-------------------------------------------------------------------------

INVESTING ACTIVITIES
Purchase of property,
 plant and equipment     (171,113)      (7,274)    (273,776)     (38,342)
Purchase of licenses            -     (175,000)    (125,000)    (175,000)
Investments in
 short-term inv.,net    1,807,736      739,032  (15,795,519)   1,738,657
-------------------------------------------------------------------------
Cash provided by
 (used in) investing    1,636,623      556,758  (16,194,295)   1,525,315
-------------------------------------------------------------------------

Net increase (decrease)
 in cash and cash
 equivalents during the
 period                    24,335    8,491,888     (252,776)   8,433,939
Cash and cash equiv.
 beginning of period      157,269       89,841      434,380      147,790
-------------------------------------------------------------------------
Cash and cash
 equivalents, end of
 period                   181,604    8,581,729      181,604    8,581,729
-------------------------------------------------------------------------
-------------------------------------------------------------------------

>>
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases